Atomo Diagnostics Ltd
ASX:AT1
Net Margin
Atomo Diagnostics Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Atomo Diagnostics Ltd
ASX:AT1
|
10.9m AUD |
-150%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
220.2B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
177.7B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
157B USD |
14%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
154.2B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
119.1B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
53.8B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
53.1B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.9B USD |
73%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.6B USD |
23%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
40.4B USD |
26%
|
Atomo Diagnostics Ltd
Glance View
Atomo Diagnostics Ltd. engages in manufacturing, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-04-16. The firm is engaged in the development and sale of medical devices. Its AtomoRapid is offering rapid diagnostic test (RDT) platform, which provides devices to the global diagnostic market. Its RDT device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. The company also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display. The company is also engaged in sales of Atomo branded COVID-19 rapid antibody and antigen tests in Australia.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Atomo Diagnostics Ltd's most recent financial statements, the company has Net Margin of -150.4%.
You don't have any saved screeners yet